India Glycols Q1FY26: Revenue Up 7%, EBITDA Up 18%, PAT Up 21%
The strong financial results and strategic initiatives, such as the Amrut partnership and restructuring plans, suggest a potentially significant positive impact on the company's future performance.
The announcement highlights strong financial performance in Q1FY26, with significant growth in revenue, EBITDA, and PAT. The company also reported positive developments in its various business segments and joint ventures.
* India Glycols Limited (IGL) reported a strong Q1FY26 performance with net revenue up 7% to ₹1,040 crore, EBITDA up 18% to ₹151 crore, and PAT up 21% to ₹73 crore. * Gross revenue increased by 10% from ₹2,283 crore to ₹2,503 crore. * EBITDA margins increased by 128 basis points, and PAT margins increased by 80 basis points. * Bio-Fuels revenue increased by 45% to ₹348 crore, and Potable Spirits revenue increased by 22% to ₹342 crore. * Chemicals (BSPC) revenue stood at ₹300 crore, while Ennature Biopharma recorded ₹51 crore. * EBIT margins for Potable Spirits improved from 17.5% to 21.1%, and for Chemicals, they expanded from 9.9% to 10.9%. * Profit from the joint venture increased by 73.7% year-on-year to ₹19 crore from ₹11 crore. * The company's Country Liquor business continues to perform well, with Bunty Bubli recognized as the highest-selling liquor brand in the country. * IGL's partnership with Amrut is gaining momentum, with a focus on premium brands and entry into the Canteen Services Department (CSD). * The company's new value-added Performance Chemicals business is growing well, with incremental capacity expansions planned. * 12th August 2025, has been fixed as a record date for determining the entitlements of eligible equity shareholders for the purpose of subdivision split of equity shares of the company. * Management Comments: * CEO, Rupark Sarswat, highlighted the strong performance in Potable Spirits and Bio-Fuel segments and noted the weaker quarter for Chemicals and Ennature Biopharma. * CFO, Anand Singhal, mentioned that the company is not planning any huge capex in the current year and will like to consolidate. About ₹325 crore is the figure, which is payable, which will be paid out of the cash accruals.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.